{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:22:55Z","timestamp":1792740175197,"version":"4.5.0"},"reference-count":33,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Current primary intracerebral hemorrhage (ICH) treatments focus on limiting hematoma volume by lowering blood pressure, reversing anticoagulation, or hematoma evacuation. Nevertheless, there is no effective strategy to protect the brain from secondary injury due to ICH. Excess heme and iron as by-products of lysing clots in ICH might contribute to this secondary injury by triggering perihematomal edema. We present a clinical situation of an ICH case where iron-chelating therapy might be beneficial, as supported by scientific evidence. We looked through four databases (Pubmed, Cochrane, Embase, and Google Scholar) to find studies assessing the efficacy of iron-chelating therapy in ICH patients. Validity, importance, and applicability (VIA) of the included articles were appraised using worksheets from the Oxford Centre for Evidence-Based Medicine. Two out of five eligible studies were valid, important, and applicable to our patient. Both studies showed the positive effects of iron-chelating therapy on neurological outcome, as measured by National Institutes of Health Stroke Scale (NIHSS) score and modified Rankin Score (mRS). The beneficial effects of deferoxamine were demonstrated within the moderate volume (10\u201330 mL) subgroup, with a positive relative risk reduction (RRR) and low number needed to treat (six persons). Based on our appraisal, we considered iron-chelating therapy as an additional therapy for ICH patients, given its benefits and adverse effects. More specific studies using a larger sample size, focusing on moderate-volume ICH, and using standardized neurological outcomes are encouraged.<\/jats:p>","DOI":"10.3390\/medicina59030453","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T02:32:12Z","timestamp":1677205932000},"page":"453","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Role of Iron-Chelating Therapy in Improving Neurological Outcome in Patients with Intracerebral Hemorrhage: Evidence-Based Case Report"],"prefix":"10.3390","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6462-7505","authenticated-orcid":false,"given":"Mochamad Iskandarsyah Agung","family":"Ramadhan","sequence":"first","affiliation":[{"name":"Dr. Cipto Mangunkusumo Hospital, Jakarta 10430, Indonesia"},{"name":"Department of Neurology, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shierly Novitawati","family":"Sitanaya","sequence":"additional","affiliation":[{"name":"Dr. Cipto Mangunkusumo Hospital, Jakarta 10430, Indonesia"},{"name":"Department of Neurology, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadri Hafian Wulandaru","family":"Hakim","sequence":"additional","affiliation":[{"name":"Dr. Cipto Mangunkusumo Hospital, Jakarta 10430, Indonesia"},{"name":"Department of Neurology, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yetty","family":"Ramli","sequence":"additional","affiliation":[{"name":"Dr. Cipto Mangunkusumo Hospital, Jakarta 10430, Indonesia"},{"name":"Department of Neurology, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/17474930211065917","article-title":"World Stroke Organization (WSO): Global stroke fact sheet 2022","volume":"17","author":"Feigin","year":"2022","journal-title":"Int. J. Stroke"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2050312118784312","DOI":"10.1177\/2050312118784312","article-title":"Cerebral small vessel disease in Indonesia: Lacunar infarction study from Indonesian Stroke Registry 2012\u20132014","volume":"6","author":"Harris","year":"2018","journal-title":"SAGE Open Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"579733","DOI":"10.3389\/fneur.2020.579733","article-title":"Outcome predictors of stroke mortality in the neurocritical care unit","volume":"11","author":"Viderman","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1161\/STR.0000000000000407","article-title":"2022 Guideline for the management of patients with spontaneous intracerebral hemorrhage: A guideline from the American heart association\/American stroke association","volume":"53","author":"Greenberg","year":"2022","journal-title":"Stroke"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/svn-2016-000042","article-title":"Brain iron overload following intracranial haemorrhage","volume":"1","author":"Garton","year":"2016","journal-title":"Stroke Vasc. Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"927334","DOI":"10.3389\/fnmol.2022.927334","article-title":"Iron neurotoxicity and protection by deferoxamine in intracerebral hemorrhage","volume":"15","author":"Li","year":"2022","journal-title":"Front. Mol. Neurosci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"603043","DOI":"10.3389\/fncel.2020.603043","article-title":"The Chemical basis of intracerebral hemorrhage and cell toxicity with contributions from eryptosis and ferroptosis","volume":"14","author":"Derry","year":"2020","journal-title":"Front. Cell. Neurosci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-211-09469-3_1","article-title":"Deferoxamine therapy for intracerebral hemorrhage","volume":"Volume 105","author":"Zhou","year":"2008","journal-title":"Cerebral Hemorrhage"},{"key":"ref_9","first-page":"239","article-title":"A Review on iron chelators in treatment of iron overload syndromes","volume":"10","author":"Mobarra","year":"2016","journal-title":"Int. J. Hematol. -Oncol. Stem Cell Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1161\/STROKEAHA.108.533125","article-title":"Deferoxamine mesylate: A new hope for intracerebral hemorrhage: From bench to clinical trials","volume":"40","author":"Selim","year":"2009","journal-title":"Stroke"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1007\/s10072-022-06324-0","article-title":"Efficacy of desferrioxamine mesylate in intracerebral hematoma: A systemic review and meta-analysis","volume":"43","author":"Zhao","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Ye, F., Wan, Y., Koduri, S., Holste, K.G., Keep, R.F., Hua, Y., and Xi, G. (2022). Too big, too small: Selecting hematoma sizes for inclusion in intracerebral hemorrhage-deferoxamine trials. Transl. Stroke Res.","DOI":"10.1007\/s12975-022-01013-8"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"101078","DOI":"10.1016\/j.inat.2020.101078","article-title":"Effects of deferoxamine treatment in patients with spontaneous cerebral hemorrhage: A meta-analysis","volume":"24","author":"Liu","year":"2021","journal-title":"Interdiscip. Neurosurg."},{"key":"ref_14","first-page":"1","article-title":"Iron chelators for acute stroke","volume":"11","author":"Aquarius","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Zeng, L., Tan, L., Li, H., Zhang, Q., Li, Y., and Guo, J. (2018). Deferoxamine therapy for intracerebral hemorrhage: A systematic review. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0193615"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1161\/STROKEAHA.121.035421","article-title":"Effect of deferoxamine on outcome according to baseline hematoma volume: A post hoc analysis of the i-DEF trial","volume":"53","author":"Wei","year":"2022","journal-title":"Stroke"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/s41582-018-0020-0","article-title":"Haemoglobin scavenging in intracranial bleeding: Biology and clinical implications","volume":"14","author":"Bulters","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"602413","DOI":"10.3389\/fneur.2020.602413","article-title":"Association of brain iron overload with brain edema and brain atrophy after intracerebral hemorrhage","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1161\/STROKEAHA.109.570168","article-title":"Iron-related brain damage in patients with intracerebral hemorrhage","volume":"41","author":"Sobrino","year":"2010","journal-title":"Stroke"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"21970","DOI":"10.1038\/srep21970","article-title":"A combination of serum iron, ferritin and transferrin predicts outcome in patients with intracerebral hemorrhage","volume":"6","author":"Yang","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_21","unstructured":"Velasquez, J., and Wray, A.A. (2022). StatPearls [Internet], StatePearls Publisher."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1161\/STROKEAHA.108.535765","article-title":"Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats","volume":"40","author":"Okauchi","year":"2009","journal-title":"Stroke"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e895","DOI":"10.1016\/j.wneu.2019.05.024","article-title":"Deferoxamine alleviates iron overload and brain injury in a rat model of brainstem hemorrhage","volume":"128","author":"Guo","year":"2019","journal-title":"World Neurosurg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1161\/STROKEAHA.111.617589","article-title":"Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage","volume":"42","author":"Selim","year":"2011","journal-title":"Stroke"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s12028-013-9861-y","article-title":"High dose deferoxamine in intracerebral hemorrhage (Hi-Def) trial: Rationale, design, and methods","volume":"19","author":"Yeatts","year":"2013","journal-title":"Neurocritical Care"},{"key":"ref_26","unstructured":"Selim, M. (2022, October 20). High-Dose Deferoxamine in Intracerebral Hemorrhage (HI-DEF), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01662895."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S1474-4422(19)30069-9","article-title":"Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): A multicentre, randomised, placebo-controlled, double-blind phase 2 trial","volume":"18","author":"Selim","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"740632","DOI":"10.3389\/fimmu.2021.740632","article-title":"perihematomal edema after intracerebral hemorrhage: An update on pathogenesis, risk factors, and therapeutic advances","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1161\/STROKEAHA.108.515262","article-title":"Variability in modified rankin scoring across a large cohort of international observers","volume":"39","author":"Quinn","year":"2008","journal-title":"Stroke"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1161\/01.STR.0000027437.22450.BD","article-title":"Improving the assessment of outcomes in stroke: Use of a structured interview to assign grades on the modified rankin scale","volume":"33","author":"Wilson","year":"2002","journal-title":"Stroke"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s12028-017-0425-4","article-title":"Functional improvement among intracerebral hemorrhage (ICH) survivors up to 12 months post-injury","volume":"27","author":"Sreekrishnan","year":"2017","journal-title":"Neurocritical Care"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"710852","DOI":"10.3389\/fneur.2022.710852","article-title":"Functional independence and disability evaluation in stroke patients: Optimal cutoff scores for a pictorial-based longshi scale, barthel index, and modified rankin scale","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/01.mph.0000194019.95096.b6","article-title":"Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients","volume":"27","author":"Chen","year":"2005","journal-title":"J. Pediatr. Hematol. \/Oncol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/3\/453\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:41:11Z","timestamp":1760121671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/3\/453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,24]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["medicina59030453"],"URL":"https:\/\/doi.org\/10.3390\/medicina59030453","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,24]]}}}